RARE
Ultragenyx Pharmaceutical Inc.
Latest Form 4:Sale$47KbyParschauer Karah Herdman (EVP and Chief Legal Officer) · filed Aug 4, 2026
Ultragenyx Pharmaceutical Inc. (RARE) has 41 SEC Form 4 filings (53 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 4, 2026.
The most active filer is Chief Financial Officer Horn Howard with 11 filings. Insiders have net sold $3.4M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Emil D. Kakkis
- Employees:1,294
- HQ:Novato, CA, US
- IPO:2014-01-31
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.0M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$2.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP and Chief Legal Officer | Sale | 1,900 | $47K | Aug 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,696 | $117K | Aug 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,698 | $156K | Jul 6 | SEC ↗ | |
| Director | Sale | 2,000 | $50K | Jun 15 | SEC ↗ | |
Parschauer Karah HerdmanFirst in 3 months | EVP and Chief Legal Officer | Sale | 1,899 | $47K | Jun 15 | SEC ↗ |
| Chief Financial Officer | Sale | 4,653 | $111K | Jun 1 | SEC ↗ | |
SULIMAN SHEHNAAZFirst filing | Director | Sale | 5,740 | $144K | May 18 | SEC ↗ |
| EVP and Chief Medical Officer | Sale | 344 | $9K | May 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,683 | $117K | May 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,683 | $98K | Apr 2 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 6,018 | $129K | Mar 10 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 3,508 | $80K | Mar 10 | SEC ↗ | |
| Chief Financial Officer | Sale | 8,409 | $191K | Mar 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,635 | $37K | Mar 3 | SEC ↗ | |
Pinion John RichardFirst filing | See Remarks | Sale | 10,029 | $229K | Mar 3 | SEC ↗ |
| SVP, Chief Accounting Officer | Sale | 1,632 | $37K | Mar 3 | SEC ↗ | |
Harris ErikFirst filing | EVP & Chief Commercial Officer | Sale | 10,539 | $240K | Mar 3 | SEC ↗ |
KAKKIS EMIL DFirst filing | President & CEO | Sale | 54,404 | $1.2M | Mar 3 | SEC ↗ |
Parschauer Karah HerdmanFirst in 6 months | EVP and Chief Legal Officer | Sale | 8,135 | $185K | Mar 3 | SEC ↗ |
| EVP and Chief Medical Officer | Sale | 7,029 | $160K | Mar 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,061 | $72K | Feb 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,150 | $72K | Jan 5 | SEC ↗ | |
Huizenga Theodore AlanFirst in 3 months | SVP, Chief Accounting Officer | Sale | 85 | $3K | Dec 30 | SEC ↗ |
| Chief Financial Officer | Sale | 3,081 | $112K | Dec 11 | SEC ↗ | |
Horn HowardFirst filing | Chief Financial Officer | Sale | 7,942 | $250K | Oct 14 | SEC ↗ |
| SVP, Chief Accounting Officer | Sale | 64 | $2K | Sep 19 | SEC ↗ | |
Parschauer Karah HerdmanFirst filing | EVP and Chief Legal Officer | Sale | 2,450 | $76K | Sep 12 | SEC ↗ |
Huizenga Theodore AlanFirst filing | SVP, Chief Accounting Officer | Sale | 84 | $3K | Sep 8 | SEC ↗ |
Related companies
Ultragenyx Pharmaceutical Inc. is in the Healthcare sector.